PDF Archive search engine
Last database update: 14 May at 16:54 - Around 76000 files indexed.
The research has been focused on mesothelioma, an asbestos-related cancer, but recently also lung and gastric cancer.
Fiona Blackhall, United Kingdom Enriqueta Felip, Spain Raffaele Califano, United Kingdom LEARNING OBJECTIVES To To To To To To To To learn about the evidence-base for lung cancer screening and novel diagnostic modalities learn about the management of early stage NSCLC and use of adjuvant treatments understand the role of m ulti-m odality treatment in locally advanced NSCLC and limited stage SCLC learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC understand the role of im m une-checkpoint blockade for lung cancer and to learn about novel im munotherapies learn about treatment of NSCLC with oligom etastatic disease learn about the systemic treatment of mesothelioma and SCLC learn about the role of supportive and palliative care for thoracic malignancies Wednesday, 11 March 2020 08:15-09:15 60’ Registration 09:15-10:55 100 SESSION 1 Screening and diagnostics for lung cancer 40’ Lung cancer screening Chairs:
It is useful in differentiating lung adenocarcinoma (+) and mesothelioma (-), as well as tumors of unknown origin in liver cancers and distinguishing cholangiocarcinoma (+) from hepatocellular carcinomas (-).
He was previously the elected Chair of the Pleural and Mediastinal Tumors Group of the TOA of the ERS for 3 years, and the Chair of the 20082009 ERS/ESTS Taskforce to establish guidelines for the management of malignant mesothelioma.
THE PROMISE AND THE PROBLEMS/ ALEX LESOKHIN, MEMORIAL SLOAN KETTERING CANCER CENTER, NEW YORK, USA 11.011.20 A NEW APPROACH FOR PANCREATIC CANCER BIOMARKER DISCOVERY USING PEPTIDOME/ DUAN CHEN, NTNU, TRONDHEIM, NORWAY 11.20- 11.40 DISCOVERY OF HYPERACETYLATED HMGB1 AS A BLOOD DIAGNOSTIC IN MESOTHELIOMA/ HAINING YANG, UNIVERSITY OF HAWAII, HONOLULU, USA 11.40- 12.00 MOLECULARLY STRATIFIED TREATMENT FOR MESOTHELIOMA/ HEDY KINDLER, UNIVERSITY OF CHICAGO, USA 12.0- 13.30 LUNCH/POSTER EXHIBITION.
Translational Research Fellow (Lung, mesothelioma and prostate) PhD, MSc and MD supervision Teaching OTHER POINTS OF NOTE:
Preclinical and clinical research for malignant mesothelioma with gene medicine and bisphosphonates.
integrated diagnosis paves the way to precision medicine 12:15 - 12:45 New insights into the molecular pathology of lobular breast carcinoma MEK and PIK3CB inhibitor combination as a promising therapeutical approach for sarcomatoid mesothelioma Dra.
ECR 2003 Final programme, February 2003, pag 420 "Role of 18F-FDG PET in management of patients with malignant pleural mesothelioma S.Fanti, C.Nanni, C.Pinto, F.Monetti, P.Castellucci, N.Monetti.
A Single-blind Randomized Phase 3 Trial of MTA plus Cisplatin versus Cisplatin in Patients with Malignant Pleural Mesothelioma sponsored by Eli-Lilly Ranbaxy Ltd.